Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Apds Telehealth topic
No spam. Unsubscribe anytime.
Committee debates APDS rules as telehealth advocates and providers press for access
Summary
Committee members and dozens of public commenters debated whether automated patient dispensing systems (APDS) may serve patients who receive care via telehealth and whether monthly in‑person inspections are required for APDS in medical offices; staff said statutory language is ambiguous and formal rulemaking may be needed for lasting clarity.
The California State Board of Pharmacy Licensing Committee opened an extensive discussion April 15 on automated patient dispensing systems (APDS) and whether the statute permits APDS placement and use tied to telehealth visits.
The committee began by reviewing relevant statutory language (Business and Professions Code §§4427.3 and 4427.6 and CCR provisions cited in meeting materials) that allows an APDS to be placed “in a medical office or other location where patients are regularly seen for purposes of diagnosis and treatment” and limits dispensing to “patients of the practice.” Committee members asked whether the existing statute and regulation are sufficiently precise about what constitutes a qualifying location and which patients qualify to receive medications via APDS.
Telehealth issue: Several public commenters representing technology developers, telehealth advocates and clinical operators urged the committee to confirm that patients who receive care via telehealth from a clinic should be considered “patients of the practice” and therefore eligible to receive medications from an APDS at that practice’s medical office. Tony E, who contracts with a medical group using kiosk-based APDS in underserved areas, said a narrow staff interpretation that requires in‑person visits would “discourage persons who would otherwise receive medical services” and hinder access in pharmacy‑desert communities.
Inspection and oversight: Industry groups also asked the board to clarify inspection expectations. Two commenters said board staff had suggested monthly in‑person pharmacist inspections for APDS units in medical offices; industry representatives said neither the cited statute nor the regulation imposes that monthly requirement for medical‑office APDS and urged the board not to add requirements beyond what the law prescribes. “Imposing requirements beyond what the law requires risks reducing APDS availability, particularly in underserved communities,” Mike Clark of the Community Care Association said.
Staff legal position and next steps: Chair Sano said the statute is not unambiguous and warned that the committee could not definitively change statutory interpretation at a committee meeting; formal regulatory clarification will likely be needed. The chair also said staff and counsel will work to confirm whether monthly inspection language applies to medical‑office APDS and to identify pathways for clearer guidance.
Broader context: Commenters and some members emphasized that APDS covers a range of technologies—from simple locker‑style pick‑up units to fully automated dispensing machines—and that the board should distinguish device types and settings when considering oversight and patient‑safety requirements.
Outlook: The committee did not adopt new rules at the meeting. Members and staff signaled they will pursue further legal review and stakeholder input; the chair advised that regulatory action may be required to resolve statutory ambiguities about location, telehealth patients, and inspection frequency.
